Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease
NCT ID: NCT02265016
Last Updated: 2021-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2014-01-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relationship Between Heme Oxygenase 1 Enzyme Level and Coronary SYNTAX Score
NCT04070014
Coronary Sinus Reducer in Patients With Angina With no Obstructive Coronary Disease
NCT07010029
Mechanisms Behind Microvascular Dysfunction in INOCA
NCT06529861
Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.
NCT01609569
A Cohort of Patients Undergoing Percutaneous Coronary Intervention
NCT05719545
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with CAD
Patients with stable coronary artery disease
No interventions assigned to this group
Patients with ACS
Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI
No interventions assigned to this group
healthy control group
healthy control group without clinical apparent arteriosclerosis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* for ACS(acute coronary syndrome)-Group: angiographic coronary artery disease; acute coronary syndrome, defined by EITHER unstable angina pectoris with significant coronary stenosis (troponin negative, without significant ST-elevation) OR low-risk NSTEMI (Troponin positive, without significant ST-elevation)
* for stable CAD-Group: angiographic coronary artery disease; no acute coronary syndrome within the last 3 months
* healthy control group: No clinical or angiographical signs of apparent atherosclerosis
Exclusion Criteria
* malignant diseases
* pregnancy
* medication with NO-donors ( e.g.isosorbide mononitrate, isosorbide dinitrate, glyceryl trinitrate, Molsidomin, Ranexa)
* patients with STEMI or high-risk NSTEMI
40 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heinrich-Heine University, Duesseldorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klinik für Kardiologie, Pneumologie und Angiologie
Principle Investigator Prof. Dr. Malte Kelm
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malte Kelm, Prof. MD
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiology, Pneumology and Angiology, University Hospital Duesseldorf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Duesseldorf
Düsseldorf, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-037
Identifier Type: OTHER
Identifier Source: secondary_id
RBC in CAD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.